Grufity logoGrufity logo

Iovance Biotherapeutics Inc Stock Research

IOVA

5.78USD-0.15(-2.53%)Market Closed

Market Summary

USD5.78-0.15
Market Closed
-2.53%

IOVA Stock Price

IOVA RSI Chart

IOVA Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-2.74

Price/Free Cashflow

-3.47

IOVA Price/Sales (Trailing)

IOVA Profitability

Return on Equity

-79.24%

Return on Assets

-59.62%

Free Cashflow Yield

-28.85%

IOVA Fundamentals

IOVA Revenue

IOVA Earnings

Earnings (TTM)

-395.9M

Earnings Y/Y

-6.03%

Earnings Q/Q

-5.72%

Price Action

52 Week Range

5.4218.73
(Low)(High)

Last 7 days

-12.7%

Last 30 days

-17.8%

Last 90 days

-5.6%

Trailing 12 Months

-65.1%

IOVA Financial Health

Current Ratio

5.24

IOVA Investor Care

Shares Dilution (1Y)

19.62%

Diluted EPS (TTM)

-2.49

Peers (Alternatives to Iovance Biotherapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
124.2B
26.3B
-2.34% 1.62%
18.96
4.72
1.32% 11.18%
98.0B
27.3B
-7.18% 37.83%
21.33
3.59
-0.09% -26.23%
57.1B
19.3B
-7.28% -16.95%
6.83
2.97
4.29% -31.47%
38.1B
10.2B
-3.01% 25.82%
12.5
3.74
-7.36% 95.80%
MID-CAP
9.2B
1.5B
-6.54% 2.94%
59.61
6.19
31.34% 72.43%
3.1B
108.5M
-20.63% -31.77%
-9.51
28.59
122.90% -12.19%
2.2B
60.9M
-22.54% -46.32%
-7.52
35.66
17.51% 22.00%
1.9B
107.9M
7.80% 19.42%
-3.99
17.93
54.84% 17.36%
SMALL-CAP
1.2B
112.0M
-12.49% -50.70%
-4.44
10.58
-70.76% -603.77%
1.1B
7.0M
-19.12% 19.58%
-7.01
156.87
131.81% -45.39%
1.1B
-
-17.78% -65.10%
-2.74
-
- -15.67%
499.9M
2.0B
-38.13% -92.75%
-0.76
0.25
72.89% 62.27%
98.0M
107.0K
-22.42% -85.54%
-0.91
915.57
-88.00% -52.91%
26.6M
-
29.52% -80.89%
-0.33
3.21
0.51% -185.61%
6.0M
1.6M
-24.22% -53.86%
-0.87
3.87
165.64% -38.13%

Financials for Iovance Biotherapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2019Q12018Q42018Q32018Q22018Q1
RevenueNaN%
Interest Expenses-0.00----
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets21.6%664546611701777
  Current Assets29.5%479370432490508
    Cash Equivalents95.8%23211810892.0078.00
  Net PPE4.5%105101101103101
Liabilities8.0%164152138149156
  Current Liabilities15.4%91.0079.0064.0077.0089.00
Shareholder's Equity26.9%500394473552622
  Retained Earnings-7.2%-1,568-1,463-1,363-1,264-1,172
  Additional Paid-In Capital11.3%2,0691,8591,8391,8181,795
Shares Outstanding19.0%188158158157157
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-8.9%-292-268-262-239-227
  Share Based Compensation0.5%84.0084.0083.0075.0070.00
Cashflow From Investing-21.2%2563252649.000.00
Cashflow From Financing5004.7%1904.0024.00190239

Risks for IOVA

What is the probability of a big loss on IOVA?

100%


Probability that Iovance Biotherapeutics stock will be more than 20% underwater in next one year

90.8%


Probability that Iovance Biotherapeutics stock will be more than 30% underwater in next one year.

79.2%


Probability that Iovance Biotherapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IOVA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Iovance Biotherapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for IOVA

Cumulative Returns on IOVA

-0.4%


10-Year Cumulative Returns

3.4%


7-Year Cumulative Returns

-19.5%


5-Year Cumulative Returns

-37.6%


3-Year Cumulative Returns

What are the long-term rolling returns for IOVA?

FIve years rolling returns for Iovance Biotherapeutics.

Annualized Returns

Which funds bought or sold IOVA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-69.97
-1,093,090
273,907
-%
2023-03-06
Rockefeller Capital Management L.P.
added
11.34
-76,000
219,000
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
-618,494
1,239,510
-%
2023-02-24
NATIXIS
new
-
6,646
6,646
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
sold off
-100
-821,000
-
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
unchanged
-
-5,987
12,013
-%
2023-02-21
MACQUARIE GROUP LTD
reduced
-11.51
-273,000
361,000
-%
2023-02-16
CHARTWELL INVESTMENT PARTNERS, LLC
sold off
-100
-447,000
-
-%
2023-02-15
ATLAS CAPITAL ADVISORS LLC
sold off
-100
-9,101
-
-%
2023-02-15
JANE STREET GROUP, LLC
added
67.58
68,262
651,262
-%

1–10 of 44

Latest Funds Activity

Are funds buying IOVA calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own IOVA
No. of Funds

Iovance Biotherapeutics News

SETE News

Perhaps timely catching Iovance Biotherapeutics Inc. (IOVA) would ....

SETE News,
6 hours ago

Yahoo Finance

Schedule 13G FIlings of Iovance Biotherapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 17, 2023
point72 asset management, l.p.
4.6%
7,347,600
SC 13G
Feb 14, 2023
avoro capital advisors llc
4.4%
7,020,000
SC 13G/A
Feb 14, 2023
perceptive advisors llc
6.3%
9,971,780
SC 13G/A
Feb 09, 2023
vanguard group inc
9.16%
14,463,082
SC 13G/A
Feb 06, 2023
wellington management group llp
0.27%
421,610
SC 13G/A
Feb 03, 2023
blackrock inc.
7.7%
12,076,276
SC 13G
Feb 02, 2023
state street corp
9.32%
14,715,475
SC 13G
Jan 13, 2023
quogue capital llc
12.52%
2e+07
SC 13D/A
Dec 30, 2022
mhr fund management llc
5.8%
10,511,920
SC 13G
Feb 24, 2022
blackrock inc.
4.7%
7,408,505
SC 13G/A

IOVA Fair Value

Recent SEC filings of Iovance Biotherapeutics

View All Filings
Date Filed Form Type Document
Mar 10, 2023
8-K
Current Report
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Feb 28, 2023
10-K
Annual Report
Feb 28, 2023
8-K
Current Report
Feb 17, 2023
SC 13G
Major Ownership Report
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 14, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for IOVA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-17
BILINSKY IGOR
sold (taxes)
-30,034
6.43
-4,671
chief operating officer
2023-01-17
BILINSKY IGOR
acquired
-
-
11,248
chief operating officer
2023-01-17
Vogt Frederick G
acquired
-
-
83,325
interim ceo & general counsel
2023-01-17
GRAF FINCKENSTEIN FRIEDRICH
sold (taxes)
-30,079
6.43
-4,678
chief medical officer
2023-01-17
GRAF FINCKENSTEIN FRIEDRICH
acquired
-
-
11,248
chief medical officer
2023-01-17
Vogt Frederick G
sold (taxes)
-234,316
6.43
-36,441
interim ceo & general counsel
2023-01-03
BILINSKY IGOR
sold (taxes)
-64,478
6.11
-10,553
chief operating officer
2023-01-03
BILINSKY IGOR
acquired
-
-
18,850
chief operating officer
2023-01-03
Bellemin Jean-Marc
acquired
-
-
18,850
chief financial officer
2023-01-03
Bellemin Jean-Marc
sold (taxes)
-64,478
6.11
-10,553
chief financial officer

1–10 of 50

Frederick G. Vogt
320
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Costs and expenses   
Research and development$ 294,781$ 259,039$ 201,727
General and administrative104,09783,66460,210
Total costs and expenses398,878342,703261,937
Loss from operations(398,878)(342,703)(261,937)
Other income   
Interest income, net2,9854512,356
Net Loss$ (395,893)$ (342,252)$ (259,581)
Net Loss Per Share of Common Stock, Basic$ (2.49)$ (2.23)$ (1.88)
Net Loss Per Share of Common Stock, Diluted$ (2.49)$ (2.23)$ (1.88)
Weighted Average Shares of Common Stock Outstanding, Basic159,259153,406138,301
Weighted Average Shares of Common Stock Outstanding, Diluted159,259153,406138,301

IOVA Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current Assets  
Cash and cash equivalents$ 231,731$ 78,229
Short-term investments240,114426,181
Prepaid expenses and other assets7,2713,546
Total Current Assets479,116507,956
Property and equipment, net105,232100,938
Operating lease right-of-use assets73,01568,983
Long-term investments 91,588
Restricted cash6,4306,084
Long-term assets1891,784
Total Assets663,982777,333
Current Liabilities  
Accounts payable26,60327,377
Accrued expenses52,29556,766
Operating lease liabilities12,5875,057
Total Current Liabilities91,48589,200
Non-Current Liabilities  
Operating lease liabilities - non-current71,85965,474
Long-term note payable1,0001,000
Total Non-Current Liabilities72,85966,474
Total Liabilities164,344155,674
Commitments and contingencies
Stockholders' Equity  
Common stock, $0.000041666 par value; 300,000,000 shares authorized, 187,812,072 and 157,004,742 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively87
Accumulated other comprehensive loss(902)(601)
Additional paid-in capital2,068,8671,794,695
Accumulated deficit(1,568,338)(1,172,445)
Total Stockholders' Equity499,638621,659
Total Liabilities and Stockholders' Equity663,982777,333
Series A Convertible Preferred Stock  
Stockholders' Equity  
Preferred stock, Value00
Series B Convertible Preferred Stock  
Stockholders' Equity  
Preferred stock, Value$ 3$ 3